- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04847999
Dark Chocolate and Glucose Levels in Diabetes
Impact of Dark Chocolate Consumption on Glucose Levels of People With Diabetes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Individuals with type 1 or type 2 diabetes (10 participants each) will consume a Ross Chocolate or conventional sugar-sweetened dark chocolate bar on two occasions in a randomized crossover trial. Blood glucose levels will be measured by finger prick for 120 minutes after consumption to determine postprandial glucose excursions after consumption of each type of chocolate bar.
Due to the COVID-19 pandemic, the trial was converted to be completed remotely/virtually with participants completing the testing at their home under the supervision of a research team member who will describe the study procedures and monitor testing via video conferencing.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1V 3G1
- University of British Columbia Okanagan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- physician-diagnosed T1D or T2D of ≥1 year;
- current HbA1c of 6.5-8.5%;
- BMI: 25-40 kg/m2;
- blood pressure of <160/99 mm Hg assessed according to guidelines;
- non-smoking;
- not on hormone replacement therapy, corticosteroids, or anti-inflammatory medications;
- 18-75 years old.
Exclusion Criteria:
- Are taking more than 2 glucose lowering medications;
- Are ongoing medical treatment for diseases such as cancer, auto-immune or inflammatory disease, liver or kidney disorders;
- Have allergy, intolerance or aversion to cocoa, stevia, erythritol, inulin, or any other dietary restrictions (e.g., vegan) that will prevent them from following the standardized study diets;
- Are unable to follow remote guidance by internet or smartphone;
- Are unable to follow the controlled diet instructions;
- Are unable to read or communicate in English.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Conventional Dark Chocolate
A standard dark chocolate bar.
|
Dark chocolate
|
Experimental: Ross Dark Chocolate
A dark chocolate bar sweetened with stevia, erythritol, and inulin.
|
Dark chocolate
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood glucose incremental area under the curve
Time Frame: Throughout study completion: 0-120 min after consumption of chocolate bar
|
A self-monitoring blood glucose device (OneTouch Verio IQ® kit Blood glucose monitoring system) will be used to measure blood glucose levels before and every 15-30 minutes after consumption of chocolates.
Incremental area under the curve will calculate the glucose above baseline fasting values across 120 minutes.
|
Throughout study completion: 0-120 min after consumption of chocolate bar
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peak blood glucose concentration
Time Frame: Throughout study completion: 0-120 minutes after consumption of chocolate bar
|
Highest blood glucose value measured after consumption of the chocolate bar
|
Throughout study completion: 0-120 minutes after consumption of chocolate bar
|
Peak blood glucose concentration above baseline
Time Frame: Throughout study completion: 0-120 minutes after consumption of chocolate bar
|
Highest blood glucose value above fasting baseline after consumption of the chocolate bar
|
Throughout study completion: 0-120 minutes after consumption of chocolate bar
|
Blood glucose total area under the curve
Time Frame: Throughout study completion: 0-120 minutes
|
A self-monitoring blood glucose device (OneTouch Verio IQ® kit Blood glucose monitoring system) will be used to measure blood glucose levels before and every 15-30 minutes after consumption of chocolates.
Total area under the curve will calculate the glucose above zero across 120 minutes.
|
Throughout study completion: 0-120 minutes
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Taste Questionnaire
Time Frame: Throughout study completion:120 min after consumption of chocolate bar
|
Self-reported taste of chocolate bars will be assessed by questionnaire
|
Throughout study completion:120 min after consumption of chocolate bar
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H20-02122
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesTerminated
Clinical Trials on Dark chocolate
-
Loma Linda UniversityCompleted
-
Queen Margaret UniversityBarry CallebautCompletedBody WeightUnited Kingdom
-
Universidad de AntioquiaTerminated
-
University of Roma La SapienzaCompleted
-
Gregoire Wuerzner; MDRecruiting
-
University of the Incarnate WordCompleted
-
University of LeipzigCompleted
-
Eastern Mediterranean UniversityCompletedCardiovascular DiseasesTurkey